Supernus Pharmaceuticals, Inc. (SUPN)
NASDAQ: SUPN · Real-Time Price · USD
42.64
+1.40 (3.39%)
Aug 13, 2025, 4:00 PM - Market closed
Supernus Pharmaceuticals Employees
Supernus Pharmaceuticals had 674 employees as of December 31, 2024. The number of employees increased by 22 or 3.37% compared to the previous year.
Employees
674
Change (1Y)
22
Growth (1Y)
3.37%
Revenue / Employee
$986,832
Profits / Employee
$95,693
Market Cap
2.39B
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
SUPN News
- 8 days ago - Supernus Pharmaceuticals, Inc. (SUPN) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 8 days ago - Supernus Announces Second Quarter 2025 Financial Results - GlobeNewsWire
- 14 days ago - Supernus Pharmaceuticals Completes Acquisition of Sage Therapeutics - GlobeNewsWire
- 17 days ago - Supernus Pharmaceuticals Announces Expiration of Hart-Scott-Rodino Waiting Period for Sage Therapeutics, Inc. Tender Offer - GlobeNewsWire
- 22 days ago - Supernus Pharmaceuticals to Announce Second Quarter 2025 Financial Results and Host Conference Call and Webcast on August 5, 2025 - GlobeNewsWire
- 4 weeks ago - SAGE THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Sage Therapeutics, Inc. - SAGE - Business Wire
- 2 months ago - ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Sage Therapeutics, Inc. - PRNewsWire
- 2 months ago - Supernus Pharma to acquire Sage Therapeutics in up to $795 million deal - Reuters